Wetherby-based Avacta, in partnership with therapeutic giant Cytiva, is developing a rapid test strip for patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the coronavirus.
Avacta said the test has the potential to be used for frequent mass testing of the population to promptly identify infectious individuals so that they can be isolated and treated, thereby reducing the spread of infection.
Abingdon Health provides rapid testing solutions to a global client base and has Europe’s largest lateral flow test contract manufacturing capacity.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.
